David Olagunju, 59, is an accomplished man. He has a B.S. degree in Mathematics, a M.S. degree in Statistics and Computer Science from Minnesota State University and he even earned 56 Graduate Credits toward a Ph.D., in Quantitative Business Analysis at the University of Florida.
What is unusual about him is that he grew up in Nigeria. Not too many Nigerians get all those degrees.
He started his career in the U.S. in 1984 as a senior data analyst and his career ended in January 2007 after twenty years of crunching numbers in the healthcare and drug industry.
During those years he dedicated his working life to Searle (now Pfizer), Genentech and Novartis.
At Novartis, his most recent job, he was Global Director, Statistical Reporting and Standards, Oncology. He started that job end of 2004.
Funny thing is, during those long twenty years in the drug industry, he didn't ever blow the whistle on anything.
Until now.
According to a lawsuit Olagunju filed in May 2007, Novartis fired Olagunju for "disclosing and refusing to participate in illegal and unethical activities regarding the testing and reporting of human drug study results concerning Tasigna (ANM), Novartis' new cancer drug."
The complaint goes on to state, "As Global Director of Oncology Statistical Reporting and Standards Reporting (SRS), plaintiff disclosed to Novartis' senior management the existence of improper statistical data being reported to the United States Food and Drug Administration (FDA), violations of established ethical standards concerning the recording and reporting of data, the failure to follow proper statistical protocols when reporting drug study data and violations of policies and procedures established to safeguard drug study participants and consumers of pharmaceutical products."
The complaint also alleges that in response to Olagunju's "complaints and in retaliation for his refusal to take part in Novartis' illegal activities and violations of public policy, he was harassed, threatened and ultimately terminated from his position at Novartis."
But here is the whopper: Plaintiff seeks a Court Order, "compelling an audit of all drug study data compiled by Novartis and provided to the FDA concerning Tasigna or any other drug utilizing Novartis' current clinical trial safety reporting system."
And before Olagunju was fired he managed to take with him some of the documents that he says proves his case. Novartis' lawyers, of course, have asked to have them returned. Olagunju replied that this wouldn't work, because he had already turned over those documents to the FDA. On June 28, to be specific, FDA sent three officals to meet with Mr. Olagunju and his attorney in NJ. And Olagunju claims the FDA people were shocked and said they would audit not just Tasigna data, but also other products.
So what about the FDA? They ain't talking. They're not denying they've talked to Olagunju, they're simply refusing to add any new information.
And Mr Olagunju's attorney, William J. Courtney, Esq., was not available for comment. And Novartis didn't get back with their side of the story.
So at this point in my research, all I had was Olagunju's allegations.
Must Read (
Well Said (
News (
Touching (
Funny (
Supported (
Interesting (
Inspiring (
Valuable (
